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Abstract
Background: The ability of the topical spot-on Advantix® (50 % permethrin/10 % imidacloprid) to prevent
transmission of Ehrlichia canis by infected Rhipicephalus sanguineus ticks to dogs has previously been reported. The
recent market introduction of chewable tablets containing the novel compounds, afoxolaner (NexGard™) and
fluralaner (Bravecto™) enabled us to conduct a comparative efficacy study with respect to the ability of these three
products to block transmission of E. canis by ticks to dogs. The speed of kill, immediate drop-off rate and
anti-attachment efficacy of the respective products were also studied.
Methods: The study was a blinded parallel group design, wherein 32 dogs were randomised into four different
groups of eight dogs. Group 1 served as negative placebo control, group 2 and 3 were treated on Days 0, 28 and
56 with NexGard™ and Advantix®, respectively. Group 4 was dosed once on Day 0 with Bravecto™. For tick efficacy
assessments 50 non-infected ticks were placed onto the dogs on Days 30, 35, 42, 49, 56, 63, 70, 77 and 84 and on
animal tick counts were performed at 3 h, 6 h and 12 h after infestation. To evaluate the ability to block transmission of
E. canis, each dog was challenged by releasing 80 adult E. canis-infected R. sanguineus ticks into their sleeping kennels
on Days 31, 38, 45 and 52. The animals were monitored for clinical signs of monocytic ehrlichiosis (pyrexia and
thrombocytopenia) and were tested for E. canis DNA by PCR and for specific antibodies using IFA. A dog was
considered infected with E. canis if both PCR and IFA yielded positive test results up to Day 84.
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Results: Mean arithmetic tick counts on dogs treated with the Advantix® spot-on were significantly (P < 0.0005) lower
throughout the study as compared with the negative controls and was, with respect to the speed of kill and resulting
onset of acaricidal efficacy, superior over NexGard™ and Bravecto™ at all time points in the 12 h period observed (3 h,
6 h and 12 h). None of the dogs treated with the Advantix® spot-on became infected with E. canis, whereas six out of
eight untreated control dogs acquired the infection. Furthermore, E. canis infection was diagnosed in four out of eight
dogs treated with NexGard™ and in two out of eight dogs treated with Bravecto™.
Conclusions: The speed of kill of the two recently registered systemic compounds against R. sanguineus was not
sufficiently fast to prevent transmission of E. canis and resulted in only low partial blocking and protection capacity
while Advantix® effectively blocked transmission of E. canis to dogs in the challenge period and thus provided
adequate protection for dogs against monocytic ehrlichiosis.
Keywords: Permethrin/imidacloprid, Afoxolaner, Fluralaner, Ehrlichia canis, Rhipicephalus sanguineus ticks, Transmission
blocking, Speed of kill
Background
Ectoparasites are no longer considered just a nuisance,
but are recognized as important vectors of disease
agents causing a range of vector-borne diseases (VBDs),
with ticks especially transmitting a great variety of infec-
tious organisms [1]. Thus evaluating the value of tick
control products should not be limited to their acaricidal
efficacy as such, but also in the light of their ability to
prevent tick-borne diseases (TBDs).
Rhipicephalus sanguineus (Latreille, 1806), the brown
dog tick, has a worldwide distribution between latitudes
50° N and 30° S, where it is predominantly encountered
on domestic dogs [2]. Recently, it has been recognized
that R. sanguineus may actually consist of several differ-
ent taxonomic entities and that currently R. sanguineus
(sensu stricto) cannot be satisfactorily assigned to any
particular population of ticks because the type specimen
has not been properly preserved as a reference [3]. Des-
pite this, the epithet R. sanguineus is used here when re-
ferring to brown dog ticks utilised in the present study.
The main importance of brown dog ticks is related to
their capacity to transmit a broad range of bacterial and
protozoan pathogens, such as Rickettsia conorii, Ana-
plasma platys (transmission suspected but not confirmed),
Babesia vogeli and Hepatozoon canis [1]. The most im-
portant bacterium, however, is Ehrlichia canis, the causa-
tive agent of canine monocytic ehrlichiosis (CME), which
distribution coincides with the distribution of the vector
tick and affects the health of dogs all over the world [4, 5].
Ehrlichia canis is a gram-negative intra-cellular bacterium
with a preference for the cytoplasm of circulating canine
monocytes. The symptomatology that ensues have been
defined as CME and include various clinical signs. Clin-
ical signs of CME, as well as laboratory findings associ-
ated with this condition, may include lethargy, fever,
anorexia, enlarged lymph nodes, pancytopenia (in par-
ticular thrombocytopenia), epistaxis [6] and the clinical
presentation can be classified as either acute, subacute
or a more chronic form [6, 7]. Doxycycline is the drug
of choice for the treatment of CME [6, 7].
Brown dog ticks are three-host ticks with all stages
adapted to dogs and as a result this tick can built up
large population densities sustained by dogs in their ken-
nels and associated human dwellings, where they also
can pose a threat to human health [8]. For example, it
was only a decade ago that the transmission of Rocky
Mountain Spotted Fever to humans in the USA could be
attributed to human-biting R. sanguineus ticks, which
are usually considered to be strictly host-specific with all
stages feeding on dogs [9]. Rhipicephalus sanguineus can
complete several cycles per year in (sub) tropical regions
of the world, whereas in the more temperature regions
there are usually discrete peaks of adult tick activity in
spring and summer, whereas in autumn immature stages
emerge on the same dog population. This is for instance
seen in the Mediterranean region [10].
Hence, effective acaricidal control of R. sanguineus is
important in order to avoid the build-up of large num-
bers of ticks as well as the prevention of chronic or fatal
canine monocytic ehrlichiosis.
A key issue with respect to any acaricidal product is
its capacity to prevent infection by blocking transmission
of pathogens that can be transmitted by ticks and may
cause disease in companion animals. This capacity de-
pends on the time it takes the product to be fully effect-
ive, but also on the time interval before the tick is able
to transmit the pathogen [11].
Comparatively little information is available regarding
the actual speed of transmission of tick-borne pathogens.
The time range for pathogen transmission varies
broadly, from immediate transmission e.g. for the TBE
(tick-borne encephalitis) virus [11] to transmission only
after one to two days of attachment e.g. for Babesia
canis [12]. For rickettsial pathogens the transmission
time is somewhat vaguely given with four to 48 h [13].
However recent studies into specific rickettsials showed
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transmission to happen earlier than previously thought.
The transmission of E. canis by R. sanguineus ticks was
shown to start within a few hours after attachment, with
dogs already infected three hours after exposure to ticks
[14]. For Rickettsia rickettsii transmission by
Amblyomma aureolatum a transmission time of > 10 h is
shown for unfed ticks, reduced to a minimum of 10 min
after attachment for ticks that had already fed [15].
Recently, clinical laboratory models have been successfully
developed to assess the capacity of ectoparasiticides for their
ability to prevent, forestall or completely block the transmis-
sion of pathogens by ticks and fleas and are additionally
used to define transmission times more precisely [16].
The first model was established for the transmission of
Babesia canis by infected Dermacentor reticulatus ticks
and examined the ability to block transmission for a com-
bination of fipronil, amitraz and (s)-methoprene [17]. This
model was consequently used to determine the blocking
capacities of a 4.5 % flumethrin and 10 % imidacloprid
collar formulation [18] and lately for afoxolaner and flura-
laner containing systemic products [19, 20].
Thereafter, a model for transmission of E. canis by in-
fected R. sanguineus ticks was established again first to
examine the blocking capacity of a combination of fipro-
nil, amitraz and (S)-methoprene [21]. This model was
subsequently also used to determine the blocking cap-
acity of a permethrin/imidacloprid spot-on formulation
[14], a 4.5 % flumethrin and 10 % imidacloprid collar
formulation [22], and recently, a novel combination of
fipronil and permethrin [23].
Recently, a novel class of orally applied systemic prod-
ucts was introduced, whose mode of action requires ticks
to attach to the host and commence feeding to become ef-
fective. For both systemic compounds published studies
demonstrated the ability to effectively block transmission
of B. canis by D. reticulatus ticks [19, 20]. However a num-
ber of studies comparing speed of kill between these novel
systemic actives and topically applied products with local
activity and repellent properties found significant differ-
ences in speed of kill within the first 12 h of attachment
[24, 25]. These results raise the question if these novel sys-
temic actives have the capacity to block transmission of
quicker transmitted pathogens.
In the study reported in this paper, we assessed the
capacity to block transmission of E. canis by infected R.
sanguineus ticks to dogs for the two recently approved
systemic compounds: afoxolaner (NexGard™, Merial
Limited, Lyon, France) [26] and fluralaner (Bravecto™,
MSD Animal Health Innovation GmbH, Schwabenheim,
Germany) [27] in comparison to a reference topical 50 %
permethrin/10 % imidacloprid spot-on formulation
(Advantix®, Bayer Animal Health, Leverkusen, Germany),
which had already shown its ability to block transmis-
sion of E. canis in the first month of application [14].
The speed of kill, immediate drop-off rate and anti-
attachment efficacy of the respective products was also
studied.
Methods
Ethical approval and study outline
This study was conducted in compliance with the Good
Clinical Practice (GCP) guideline (Veterinary Inter-
national Conference on Harmonization GL9) [28] and
the European Medicines Agency guidelines regarding
testing of anti-parasitic substances for treatment and
prevention of tick and flea infestation in dogs and cats
[29]. Ethical approval for conduct of the study was ob-
tained from the “Clinvet Committee for Animal Ethics
and Welfare” ethics body prior to conduct of the study.
The study was performed using purpose-bred dogs
belonging to Clinvet, at the Clinvet study site near
Bloemfontein, Free State, South Africa. The study was
randomised, blinded and employed a parallel group de-
sign. Inclusion criteria for dogs into the study were:
clinically healthy, older than six months, not clinically
pregnant, not treated with any ectoparasiticide for at
least 12 weeks prior to the start of the study, sero-
negative for E. canis by immunofluorescence assay
(IFA) and negative for E. canis deoxyribonucleic acid
(DNA) by polymerase chain reaction (PCR). Thirty-two
purpose-bred beagles and mongrels belonging to Clin-
vet that complied with these inclusion criteria were di-
vided into weight ranges (< 10 kg; > 10 kg to 20 kg;
and > 20 kg). Health status at inclusion was confirmed
by a veterinarian during clinical examination. Dogs
were ranked within sex (14 males and 18 females) in
descending order of individual live tick counts prior to
veterinary product or placebo administration, and sub-
sequently blocked into eight blocks of four dogs each.
Within blocks, dogs were randomly allocated to four
groups using Microsoft Excel software. A non-blinded
person randomly assigned the groups to four coded
groups using the same software package. Blinded
personnel only had access to group codes and not
group numbers. The study was thus conducted on four
groups of eight dogs each. All dogs, identifiable by a
microchip number, were individually housed in tick-
proof kennels and observed daily throughout the dur-
ation of the study. In order to eliminate possible bias,
additionally to the use of a placebo spot-on product,
persons involved in the post-treatment observations
were different from those that performed group alloca-
tions and treatments.
The study was laid out over a timeframe of three
months (84 days), with the actual challenge periods in
month two (Days 28 to 56) for E. canis transmission
blocking and months two and three (Days 28 to 84) for
tick efficacy assessments.
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Treatments and rescue treatments
Dogs allocated to group 1 served as negative control and
received a placebo spot-on compound (mineral oil), dogs
in group 2 were treated with Advantix® spot-on solution
for dogs (50 % permethrin/10 % imidacloprid), those in
group 3 received NexGard™ chewable tablets for dogs
(afoxolaner) and those in group 4 received Bravecto™
chewable tablets for dogs (fluralaner). Treatment regime
is shown in Fig. 1 including placebo compound adminis-
trations for orally treated groups. Bravecto™ chewable
tablets were administered on Day 0 only, based on the
up to three month efficacy against ticks registered label
claim of this product. All products were administered
within weight classes as per label instructions. The pla-
cebo treatment applied to dogs in the Control group as
well as the orally treated NexGard™ and Bravecto™ groups
consisted of mineral oil only and was applied in three or
four spots along the midline of the back. In the Advantix®-
treated group between 10.42 mg/kg and 24.51 mg/kg imi-
dacloprid and between 52.08 mg/kg and 122.55 mg/kg
permethrin were applied by parting the hair and applying
the product directly onto the skin in three or four spots
along the midline of the back. In the NexGard™-treated
group between 2.54 mg/kg and 5.48 mg/kg afoxolaner
were administered orally. In the Bravecto™-treated group
between 25.25 mg/kg and 47.62 mg/kg fluralaner were ad-
ministered orally.
Animals were screened weekly using PCR and IFA. A
positive PCR result provided confirmation of clinical diag-
nosis and hence the necessity to perform rescue treatment.
Animals that tested negative (both PCR and IFA) on the
last day of the study were not rescue-treated. Six animals in
control group 1, no animals in Advantix® group 2, four ani-
mals in NexGard™ group 3 and two animals in Bravecto™
group 4 were rescue-treated with a commercial product
containing doxycycline (Doxydog 100 mg and 50 mg,
registration numbers G2636 and G2688 respectively) at the
recommended dose rates and treatment regime.
Tick efficacy assessments
Efficacy assessments focused on early time points after
tick infestation as defined in the following sections:
Tick infestations for efficacy assessments
A laboratory-bred strain of pathogen-free R. sanguineus
(European origin, French strain) was used for artificial in-
festations. Each dog was infested with 50 ticks on days in-
dicated in Fig. 2. Dogs (not sedated) were placed in an
infestation crate, followed by the placement of 50 ticks on
the dogs. The dogs were subsequently restrained inside
the crates for 10 min before closing the mesh cover to
confine the animal in the crate for a period of 12 h. Ticks,
which dropped off the dogs during the first 10 min, were
not placed back, unless shaken off by the dog.
Tick counting procedures
The tick counting procedures were designed to allow cal-
culation of speed of kill, immediate drop-off and anti-
attachment efficacy as described in the sections to follow,
which in turn aided in the interpretation of efficacy in pre-
venting E. canis transmission. On animal tick counts for
speed of kill assessment at 3 h, 6 h and 12 h after infest-
ation were performed on Days 30, 35, 42, 49, 56, 63, 70,
77 and 84. In situ thumb counts were performed 3 h (±
15 min) and 6 h (± 30 min) after each infestation. During
these in situ counts, sexes were not distinguished, but
ticks were categorised as live or dead. Calculation was per-
formed according to the most current guidelines [30] and
as a result engorgement status was not considered during
efficacy calculations. Tick removal counts were performed
12 h (± 30 min) after each infestation. During removal
counts ticks were counted within sex (male or females)
Fig. 1 Treatment time point layout
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and same general status as defined for the in situ counts.
On the days and time points specified for in situ counts
above, the ticks that dropped off the dogs were collected
from the infestation crates. Collection took place during
the time the dog was removed from the infestation crate
for tick counts.
Methods for calculating efficacy and comparing groups
All efficacy results reported were based on arithmetic
means as requested by current guidelines [30].
The speed of kill efficacy was calculated as the acari-
cidal efficacies [30] for the treated groups at the different
assessment time points (3 h and 6 h in situ and 12 h re-
moval counts). Speed of kill efficacy calculations were
based on arithmetic mean tick counts using Abbott’s
formula:
Speed of kill efficacy %ð Þ ¼ 100  Mc–Mtð Þ=Mc
where Mc = Arithmetic mean number of live ticks on
dogs in the control group at a specific time point and
Mt = Arithmetic mean number of live ticks on dogs in
the respective treated groups at a specific time point.
The immediate tick drop-off rate was calculated
based on the number of ticks recovered off the animal
(i.e. free in the infestation crate) within 3 h of infestation
as follows:
Immediate drop‐off rate %ð Þ
¼ 50–Mcð Þ– 50–Mtð Þ½ = 50–Mcð Þ  100
where Mc = Arithmetic mean number of total ticks col-
lected off animal in the control group at the 3 h time
point and Mt = Arithmetic mean number of total ticks
collected off animal in the respective treated groups at
the 3 h time point.
The anti-attachment efficacies at 6 h and 12 h post-
infestation were calculated based on attached tick counts
on dogs only. The aim was to evaluate if ticks that
remained on the animals at 3 h after infestation actually
attached to the animals by 6 and 12 h, respectively as
follows:
Anti‐attachment efficacy %ð Þ
¼ 100  Tmc–Tmtð Þ=Tmc
where Tmc = Total attached (arithmetic mean of live
and dead) ticks on the dogs in the control group at the
respective time point, and Tmt = Total attached (arith-
metic mean of live and dead) ticks on the dogs in the re-
spective treated groups at the respective time point.
The groups were compared using an ANOVA after a
logarithmic transformation on the tick (count + 1) data.
The proportion of animals in each group was also com-
pared. SAS Version 9.3 TS Level 1 M2 was used for all
the statistical analyses. The level of significance was set
at 5 %; all tests were two-sided.
Tick infestations to assess Ehrlichia canis blocking efficacy
and monitoring of infection
Ticks used in this study derived from the same laboratory-
bred strain of R. sanguineus used for the acaricidal efficacy
determination and were artificially infected with a South
African strain of E. canis using methods previously pub-
lished [16, 31]. In order to simulate environmental tick
challenges, ticks were released into the sleeping kennels of
dogs on days indicated in Fig. 2. Ticks used were unfed, at
least two weeks old and had a balanced sex ratio. The aver-
age infection rate of the tick batch used was 3.8 % and 80
ticks were released into each kennel to ensure an adequate
environmental challenge.
Following environmental challenges ticks were removed
after four days on Days 35, 42, 49 and 56. Moreover, each
sleeping kennel was visually inspected for detached ticks,
which were removed and the kennel cleaned.
Fig. 2 Tick challenge time point layout
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Infection with E. canis was monitored by clinical ex-
aminations, rectal temperature records, platelet counts,
as well as by testing blood samples by PCR and IFA.
All animals were observed daily for general health. Also
clinical examinations (all dogs) were performed during ac-
climatisation for inclusion purposes, as well as on Days -1,
27, 34, 41, 48, 55, 62, 69, 76 and 83. Rectal body tempera-
tures were recorded at least three times per week from
Day 35 to Day 84. When dogs displayed abnormally high
body temperatures (> 39.4 °C), a further measurement was
taken the following day to evaluate for persistent pyrexia.
Blood specimens were collected for E. canis DNA de-
tection by PCR and for platelets counts on Days -8, 30,
35, 42, 49, 56, 63, 70, 77 and 84. As PCR target, a spe-
cific fragment of the dsb gene of E. canis was amplified
according to conditions previously published [23]. Con-
ventional PCR was employed for detection of E. canis in
animal blood and quantitative real-time PCR was
employed for parasite load detection. Platelets counts
were conducted by PathCare Veterinary Laboratory.
Platelet concentration was evaluated as part of the
complete blood count (CBC). The concentration was
determined using a laser optic method. Smear exami-
nations were performed on all abnormal platelet
concentrations.
Serum was collected on Days -6, 35, 42, 49, 56, 63, 70,
77 and 84 and frozen at -20 °C until assayed for the de-
tection of specific E. canis antibodies using a commercial
IFA test kit (Megascreen® Fluoehrlichia c. test kit manu-
factured by MegaCor Diagnostik, Hörbranz, Austria).
IgG titres of 1:40 and greater were considered to reflect
infection (i.e. positive result).
Additional clinical examinations to that specified on
the before mention days were conducted on any animal
that displayed signs associated with ehrlichiosis. These
signs included, but were not limited to, persistent pyr-
exia, thrombocytopenia and lethargy. For all animals
with suspected ehrlichiosis, additional blood speci-
mens for PCR were collected as needed to confirm
the diagnosis.
Whilst a positive PCR result provided confirmation of
clinical diagnosis and hence the necessity to perform
rescue treatment, an efficacy failure (successfully in-
fected with E. canis as employed in blocking and risk re-
duction calculations as described below) was defined as
a dog that was found positive for E. canis DNA by PCR
analysis and also seroconverted (tested positive for E.
canis antibodies).
Methods for calculating the Ehrlichia canis blocking
efficacy
The blocking efficacy per infected animal considers
the number of animals that were successfully infected.
Blocking efficacy per infected animal for the treat-
ment group was calculated as follows:
Blocking efficacy %ð Þ ¼ 100 Tc−Ttð Þ=Tc
where Tc = Total number of infected dogs in the nega-
tive control group and Tt = Total number of infected
dogs in the respective treatment group.
Whilst this is the simplest calculation method, the
underlying assumption is that all animals were exposed to
the same challenge pressure, which is not always the case.
Navarro et al. (2015) [32] first employed the number
of infective challenges in their calculation method, as de-
duced from one of the result tables. Jongejan et al.
(2015) [23] first defined a formula for this calculation
method, that considers not solely number of infected an-
imals but calculates the percentage of protection in com-
parison to the number of infective challenges.
Percentage of protection was defined and calculated
as follows:
Protection %ð Þ ¼ 100  IcC−IcTð Þ=IcC
where IcC = the “infection proportion” calculated as the
number of infected animals in the control group divided
by the total number of pre-infection challenges with
ticks from a batch infected with E. canis in the control
group and IcT = the “infection proportion” calculated as
the number of infected animals in the respective treat-
ment groups divided by the total number of pre-
infection challenges with ticks from a batch infected
with E. canis in the respective treatment groups.
Results
No adverse events related to administration of any of the
veterinary products assessed occurred during this study.
On animal tick count results
Mean tick counts on animals in the control group indi-
cated that an adequate infestation was reached on all as-
sessment days and all assessment time points: 3 h
(Table 1), 6 h (Table 2) and 12 h (Table 3).
In the NexGard™-treated group the mean tick numbers
were significantly lower compared to the Control group
only at the 6 h time point on Day 42 (F(3,28) = 32.17, P =
0.0366) and at the 12 h point on Day 30 (F(3,28) = 14.56, P =
0.0288). In the Bravecto™-treated group mean tick counts
were significantly lower compared to the Control group
only at the 12 h time points from Day 30 through to Day
56 (F(3, 28) ranged between 14.56 and 22.62 with P-values
ranging between 0.0007 and 0.0402).
Mean tick numbers were significantly lower on all as-
sessment days when comparing the Advantix®-treated
group to the Control group at 3 h, 6 h and 12 h.
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Speed of kill efficacy
The comparative speed of kill induced by each of the
three ectoparasiticides is illustrated in Fig. 3 for 3 h,
Fig. 4 for 6 h and Fig. 5 for 12 h post-infestation, re-
spectively. Speed of kill efficacy for the NexGard™-
treated group ranged from 0 % (at the 6 h time point on
Day 84 and 12 h time points on Days 56, 77 and 84) to
38.4 % (at the 12 h time point on Day 63) and exceeded
30 % on only two occasions, namely at the 12 h point on
Days 63 and 70. Speed of kill efficacies for the
Bravecto™-treated group ranged from 0 % (at the 3 h
time point on Day 30, the 6 h time points on Days 30,
35 and 70 and the 12 h time point on Day 84) to 55.2 %
(at the 12 time point on Day 42) which was also the only
time point where efficacy exceeded 50 %. In the Advan-
tix®-treated group the speed of kill efficacy ranged from
79.6 % (at the 3 h time point on Day 30) to 99.2 % (at
the 12 h time point on Day 84) and exceeded 80 % at all
assessment points with the exception of the 3-h point on
Day 30.
Immediate drop-off rate
The immediate drop-off rate (Table 4) assessed 3 h after
infestation for the NexGard™ and Bravecto™-treated
groups ranged from 0 % (both groups with time points
defined in next sentence) to 7.8 and 3.8 % (both on Day
77), respectively. The NexGard™ group presented with
0 % efficacy on Days 30, 35, 42, 56, 63, 70 and 84, whilst
the Bravecto™ the group presented with 0 % efficacy on
Days 30, 42, 49, 63 and 70. The immediate drop-off rate
for the Advantix®-treated group ranged from 58.3 % (on
Day 63) to 77.7 % (on Day 42).
Anti-attachment efficacy
For the NexGard™-treated group anti-attachment efficacy
ranged from 0 % (at the 6 and 12 h time point on Day 84)
Table 1 Mean arithmetic on animal tick counts three hours after infestation of dogs with Rhipicephalus sanguineus
Day Arithmetic mean tick counts 3 hours after infestationa
Control Advantix® NexGard™ Bravecto™
M M F df P M F df P M F df P
Day 30 49.4 15.6 86.69 3 < 0.0001 49.5 86.69 3 0.9615 49.4 86.69 3 1.0000
Day 35 47.0 14.4 76.37 3 < 0.0001 48.0 76.37 3 0.7100 46.8 76.37 3 0.9258
Day 42 48.1 10.8 184.50 3 < 0.0001 48.3 184.50 3 0.9499 49.5 184.50 3 0.4916
Day 49 47.4 12.0 184.57 3 < 0.0001 46.8 184.57 3 0.7412 49.6 184.57 3 0.2399
Day 56 47.6 16.9 207.73 3 < 0.0001 48.5 207.73 3 0.5693 47.4 207.73 3 0.8705
Day 63 44.4 18.5 33.43 3 < 0.0001 46.4 33.43 3 0.5648 48.4 33.43 3 0.2537
Day 70 46.4 11.3 80.02 3 < 0.0001 46.5 80.02 3 0.9652 48.5 80.02 3 0.4606
Day 77 46.4 13.6 39.97 3 < 0.0001 42.8 39.97 3 0.3063 44.6 39.97 3 0.6188
Day 84 48.6 12.0 311.86 3 < 0.0001 48.6 311.86 3 1.0000 48.3 311.86 3 0.7994
Abbreviations: M arithmetic mean, F, F-statistic, df, degrees of freedom, P, P-value (one-way ANOVA with a treatment effect in comparison with control group)
acounts based on ticks attached to the dogs, excluding ticks in the crates
Table 2 Mean arithmetic on animal tick counts six hours after infestation of dogs with Rhipicephalus sanguineus
Day Arithmetic mean tick counts 6 hours after infestationa
Control Advantix® NexGard™ Bravecto™
M M F df P M F df P M F df P
Day 30 20.1 3.3 8.12 3 0.0005 15.5 8.12 3 0.2920 22.9 8.12 3 0.5283
Day 35 35.0 3.4 17.07 3 < 0.0001 27.3 17.07 3 0.1092 26.9 17.07 3 0.0939
Day 42 31.6 2.3 32.17 3 < 0.0001 24.5 32.17 3 0.0366 26.6 32.17 3 0.1346
Day 49 35.4 1.1 27.53 3 < 0.0001 34.6 27.53 3 0.8665 31.1 27.53 3 0.3444
Day 56 33.4 2.6 16.24 3 < 0.0001 29.3 16.24 3 0.4017 26.1 16.24 3 0.1457
Day 63 32.0 6.3 9.30 3 < 0.0001 25.8 9.30 3 0.2447 27.1 9.30 3 0.3619
Day 70 27.6 0.6 34.78 3 < 0.0001 24.6 34.78 3 0.3224 23.4 34.78 3 0.1646
Day 77 25.5 2.6 10.24 3 < 0.0001 23.4 10.24 3 0.6452 18.1 10.24 3 0.1175
Day 84 32.4 1.8 59.82 3 < 0.0001 34.9 59.82 3 0.3882 31.1 59.82 3 0.6646
Abbreviations: M, arithmetic mean; F, F-statistic; df, degrees of freedom; P, P-value (one-way ANOVA with a treatment effect in comparison with control group)
acounts based on ticks attached to the dogs, excluding ticks in the crates
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to 39.5 % (at 12 h on Day 63). For the Bravecto™-treated
group anti-attachment efficacy ranged from 0 % (at the
6 h time point on Day 30 and the 12 h time point on Day
84) to 56.3 % at 12 h on Day 42. In the Advantix®-treated
group the anti-attachment efficacy ranged between 79.8 %
at the 12 h time point on Day 63 and 99.2 % at the 12 h
time point on Day 84 (Tables 5 and 6).
Ehrlichia canis blocking efficacy
In general, clinical signs, fever and reduced platelet
counts, observed in dogs enrolled in the studies could be
linked to the tick-transmitted infections (Table 7). All dogs
diagnosed with E. canis were pyretic, except for three dogs
in the Control group and one dog in the NexGard™-
treated group. However, in some instances in all four
groups, elevated temperature (> 39.4 °C) did not result in
a confirmed diagnosis with E. canis and were attributed to
animals being excited. Also, not all animals diagnosed in-
fected with E. canis were thrombocytopenic (platelet
counts < 200). Thrombocytopenia was detected in four
out of six infected animals in the Control group, three out
of four infected animals in the NexGard™-treated group
and both infected animals in the Bravecto™-treated group.
Six out of eight dogs in the Control group became
positive for E. canis DNA based on PCR analysis, indi-
cating a successful infection challenge and consequently
seroconverted. Four animals in the NexGard™-treated
group and two animals in the Bravecto™-treated group
tested positive for E. canis DNA and all of these ani-
mals also seroconverted. None of the animals in the
Table 3 Mean arithmetic on animal tick counts 12 hours after infestation of dogs with Rhipicephalus sanguineus
Day Arithmetic mean tick counts 12 hours after infestationa
Control Advantix® NexGard™ Bravecto™
M M F df P M F df P M F df P
Day 30 35.3 3.5 14.56 3 < 0.0001 24.0 14.56 3 0.0288 22.5 14.56 3 0.0143
Day 35 31.8 0.9 15.15 3 < 0.0001 25.6 15.15 3 0.2202 16.3 15.15 3 0.0036
Day 42 35.5 2.3 16.27 3 < 0.0001 30.1 16.27 3 0.3156 15.5 16.27 3 0.0007
Day 49 34.5 1.5 22.62 3 < 0.0001 33.1 22.62 3 0.7640 24.3 22.62 3 0.0318
Day 56 33.6 1.9 16.01 3 < 0.0001 34.9 16.01 3 0.8187 22.0 16.01 3 0.0402
Day 63 28.5 5.8 5.77 3 0.0003 17.3 5.77 3 0.0507 19.5 5.77 3 0.1136
Day 70 26.6 0.3 24.65 3 < 0.0001 20.1 24.65 3 0.0714 25.1 24.65 3 0.6687
Day 77 24.6 3.9 7.68 3 0.0002 24.0 7.68 3 0.9001 19.0 7.68 3 0.2639
Day 84 31.8 0.3 55.67 3 < 0.0001 36.0 55.67 3 0.1986 22.9 55.67 3 0.5283
Abbreviations: M, arithmetic mean, F, F-statistic, df, degrees of freedom, P, P-value (one-way ANOVA with a treatment effect in comparison with control group)
acounts based on ticks attached to the dogs, excluding ticks in the crates
Fig. 3 Speed of kill efficacy against Rhipicephalus sanguineus ticks on dogs 3 h after infestation
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Advantix®-treated group were positive for E. canis
DNA and neither became positive for E. canis anti-
bodies based on IFA analysis (Table 7).
The challenge periods and number of animals success-
fully infected are graphically presented in Fig. 6. The total
number of successful challenges with ticks from an E.
canis infected batch were 29 for the Control group and 32
for each of the respective treated groups (Advantix®, Nex-
Gard™ and Bravecto™. Fewer challenges were performed
for the Control group as three animals were confirmed
positive for E. canis DNA per PCR on Day 49, hence
rescue-treated, and not challenged again on Day 52.
The blocking efficacy determined was 33.3 % for Nex-
Gard™ and 66.7 % for Bravecto™. Advantix® fully blocked
(100 %) transmission of E. canis to dogs over the chal-
lenge period (Table 8).
Calculating the protection conferred against infective
tick challenges, (Fig. 6) [23], NexGard™ provided 39.6 %
and Bravecto™ 69.8 % protection against transmission of
E. canis to dogs compared to 100 % protection evaluated
for Advantix® (Table 9).
Discussion
In this study we assessed the capacity to block transmis-
sion of E. canis by infected R. sanguineus ticks to dogs
for two systemic compounds: afoxolaner (NexGard™,
Merial Limited) [26] and fluralaner (Bravecto™, Intervet
International) [27] in comparison to a reference topical
50 % permethrin/10 % imidacloprid spot-on formulation
(Advantix®, Bayer Animal Health), which had previously
shown its ability to block transmission of E. canis in the
first month of application [14]. The speed of kill, imme-
diate drop-off rate and anti-attachment efficacy of the
three products were also studied.
The study lay out over a timeframe of three months
(84 days) was owed to the fact that it compared two
products licensed for monthly use (NexGard™, Advan-
tix®) against a 3 months product (Bravecto™ that,
Fig. 4 Speed of kill efficacy against Rhipicephalus sanguineus ticks on dogs 6 h after infestation
Fig. 5 Speed of kill efficacy against Rhipicephalus sanguineus ticks on dogs 12 h after infestation
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however, for R. sanguineus has a two months label only
in the EU. The challenge period for E. canis blocking in
month 2 of the study, was chosen to include the end of
the licensed efficacy period (according to the EU label)
(Days 28 to 56, with first environmental tick challenge
on Day 31 and last environmental tick challenge on Day
52), while challenges for tick efficacy commenced until
the end of month 3 (Days 28 to 84, with first infestation
for tick efficacy assessments with subsequent counts on
Day 30 and last on Day 84). Advantix® was used as a ref-
erence product as its ability to block the transmission of
E. canis in the first month after application was previ-
ously shown [16]. This earlier study showed the four
week efficacy against R. sanguineus ticks to range be-
tween 96.1 and 98.9 % at 48 h post tick challenge. Four
out of six control dogs developed clinical signs of CME
and required treatment, whereas none of the treated
dogs became infected with E. canis, resulting in a block-
ing efficacy of 100 % [16].
In the current study on animal tick counts in the Advan-
tix®-treated group were significantly lower throughout the
study compared to counts on negative control dogs
(Tables 1, 2 and 3). In contrast, on animal tick counts in
the groups treated systemically (NexGard™, Bravecto™ were
not significantly lower compared to the counts in the con-
trol group with the exception of few singular time points.
The protective ability of a topically applied acaricide
with topical efficacy is due to its efficacy on contact,
prior to potential attachment and feeding [16]. As for
systemic acaricides the ticks need to attach to the
treated host and start to take a blood meal before being
killed in the process, the protection afforded is less obvi-
ous. Therefore, in the light of risk reduction for trans-
mission of disease pathogens it needs to be evaluated
specifically regarding its onset of efficacy.
The high drop-off rate within 3 h seen for Advan-
tix® due to its permethrin component was not ex-
pected to be similar in the groups treated with the
systemic compounds, which was confirmed by the
results (Table 4).
Similarly, the subsequent anti-attachment efficacy,
which evaluated if ticks remaining on the animals at 3 h
after infestation actually attached to the animals by 6 h
and 12 h, respectively, was lower in the orally treated
groups (NexGard™, Bravecto™) than in the Advantix®-
treated group, concurring with the need of ticks to
attach and take a blood meal to be exposed to the
systemically acting actives.
Speed of kill efficacies at 3 h, 6 h and 12 h after tick in-
festation, showed the efficacy for the NexGard™-treated
group to exceeded 30 % only at the 12 h time points on
Days 63 and 70 (Table 6). Likewise, speed of kill efficacies
for the Bravecto™-treated group exceeded 50 % only on a
single occasion at 12 h on Day 42 (Table 6). 0 % efficacy
was measured for both oral products at the 12 h point on
Day 84 at the end of the study the efficacy (Table 6). This
means that tick count numbers were not significantly dif-
ferent any longer from the level encountered on dogs of
the negative control group (Table 3). With respect to
speed of kill and resulting onset of acaricidal efficacy,
Advantix® was superior over NexGard™ and Bravecto™ at
all time points (3 h, 6 h and 12 h) in the 12 h period ob-
served (Figs. 1, 2 and 6).
Table 4 Immediate drop off rate (expressed as a percentage
based on arithmetic means) three hours after tick infestation
Day Advantix® NexGard™ Bravecto™
Day 30 68.4 0 0
Day 35 69.4 0 0.5
Day 42 77.7 0 0
Day 49 74.7 1.3 0
Day 56 64.6 0 0.5
Day 63 58.3 0 0
Day 70 75.7 0 0
Day 77 70.6 7.8 3.8
Day 84 75.3 0.0 0.8
Table 5 Anti-attachment efficacy (based on arithmetic means)
six hours after tick infestation
Day Advantix® NexGard™ Bravecto™
Day 30 83.9 23.0 0
Day 35 90.4 22.1 23.2
Day 42 92.9 22.5 15.8
Day 49 96.8 2.1 12.0
Day 56 92.1 12.4 21.7
Day 63 80.5 19.5 15.2
Day 70 97.7 10.9 15.4
Day 77 89.7 8.3 28.9
Day 84 94.6 0.0 3.9
Table 6 Anti-attachment efficacy (based on arithmetic and
geometric means) 12 hours after tick infestation
Day Advantix® NexGard™ Bravecto™
Day 30 90.1 31.9 36.2
Day 35 97.2 19.3 48.8
Day 42 93.7 15.1 56.3
Day 49 95.7 4.0 29.7
Day 56 94.4 0 34.6
Day 63 79.8 39.5 31.6
Day 70 99.1 24.4 5.6
Day 77 84.3 2.5 22.8
Day 84 99.2 0 0
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The high variability in efficacy seen at these early as-
sessment time points is assumed to depend largely on
the actual time point at which the ticks attach and com-
mence feeding after infestations. This differs for topically
applied products with topical efficacy, which start to
work on contact, thus directly at infestation and prior to
potential attachment and feeding [16].
The speed of kill efficacies observed in our study for
NexGard™ and Bravecto™ against R. sanguineus are slightly
lower than those obtained in earlier publications for early
time points, however, follow the same trend regarding
variability. Varloud et al. (2015) found speed of kill effica-
cies (based on geometric means) 12 h after infestation
ranging between 21–49 % for NexGard™ and 58–89 % for
Bravecto™ [24]. Ohmes et al. (2015) found speed of kill ef-
ficacies (based on geometric means) for NexGard™ ran-
ging between 0–26 % 3 h after infestation and 12–45 %
12 h after infestation and for Bravecto™ ranging between
13–26 % 3 h after infestation and 52–98 % 12 h after
infestation [25].
Similarly to the higher variability seen in the efficacy
of systemic acaricides at early time points, it is also ex-
pected to see a higher variability in the efficacy between
different tick species due to differences in attachment
and feeding behaviour [16]. For instance, the immediate
speed of kill efficacy published for NexGard™ against
Ixodes ricinus was reported to reach 93.4 % within 12 h
post treatment with the persistent speed of kill at the
12 h time point ranging between 76.6 % on Day 7 and
38.5 % on Day 28 [33]. For Bravecto™ the speed of kill ef-
ficacy against existing infections (immediate speed of
kill) with I. ricinus was found to be 89.6 % at 4 h, 97.9 %
at 8 h and 100 % at 12 h after treatment. The speed of
kill efficacy against reinfections (persistent speed of kill)
against I. ricinus was found to range from 33.2 % in
week four after treatment to 7.8 % in week 12 after treat-
ment at 4 h, from 96.8 % in week four after treatment to
45.8 % in week 12 after treatment at 8 h and from
99.7 % in week four after treatment to 98.3 % in week 12
after treatment at 12 h [34].
However speed of kill efficacies are ultimately only an
indicator for the potential to block transmission of dis-
ease pathogens. A key issue with respect to any acari-
cidal product is its capacity to prevent infection by
blocking transmission of pathogens that can be trans-
mitted by ticks and may cause disease in companion
animals. This capacity depends on the time it takes the
product to be fully effective, but also on the time inter-
val before the tick is able to transmit the pathogen [16].
This is the first study wherein both afoxolaner as well
as fluralaner have been tested for their ability to prevent
transmission of E. canis. The E. canis infected R. sangui-
neus tick batch used for challenges in this study had an
average infection rate of 3.8 %. Prevalence reported for
E. canis in R. sanguineus ticks from field collections
range between 0.09–27 % [35–38], varying widely be-
tween different endemic areas. The use of 80 ticks per
challenge resulted in an adequate infection, as 6 out of
the 8 control animals got infected.
The capacity of the two systemic compounds to
block transmission of E. canis by infected R. sanguineus
ticks to dogs over the challenge period was assessed to
be 33.3 % for NexGard™ and 66.7 % for Bravecto™.
Table 7 Monitoring of Ehrlichia canis transmission by infected
Rhipicephalus sanguineus ticks to dogs
Group Animal ID Tempa Plateletsb PCR IFA
(1) Control 2A7 53C 40.1 199 NEG NEG
2AA 200 39.3 114 POS POS
4C6 76B 39.9 226 POS POS
4C6 FCC 40.5 155 POS POS
500 362 38.9 257 POS POS
CC1 5A3 40.6 172 POS POS
CD0 4 F5 38.8 204 NEG NEG
DF7 4DB 39.3 132 POS POS
(2) Advantix® 284 012 38.8 392 NEG NEG
2AA 66 F 39.5 251 NEG NEG
2 AD 36C 40.3 347 NEG NEG
4C7 17D 40.6 396 NEG NEG
4DD 2E5 40.0 252 NEG NEG
4 F4 A1D 39.4 323 NEG NEG
B2B 7D0 40.4 13 NEG NEG
CD3 EC5 39.6 218 NEG NEG
(3) NexGard™ 289 BB6 40.6 264 NEG NEG
2 AC 905 40.5 70 POS POS
4DE 28 F 39.9 145 POS POS
4EF 726 40.1 27 POS POS
B2B 745 39.9 314 NEG NEG
CBF E82 39.0 231 POS POS
DF7 5C1 39.9 320 NEG NEG
E17 7C8 39.3 248 NEG NEG
(4) Bravecto™ 285 8A5 40.1 356 NEG NEG
2A8 C98 40.8 103 POS POS
4D9 0DB 40.3 134 POS POS
4 F7 4B1 39.6 362 NEG NEG
5D3 A6A 39.0 225 NEG NEG
E16 E41 39.0 227 NEG NEG
E17 4A6 39.3 184 NEG NEG
E18 950 39.4 202 NEG NEG
aMaximum body temperature measured (> 39.4 °C is significant)
bMinimum platelet counts as a measure for thrombocytopenia (normal range
between 200 × 109/l and 500 × 109/l)
Abbreviations: POS, Positive, NEG, Negative
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Advantix® effectively blocked transmission of E. canis
to dogs by 100 % for the challenge period (Table 8),
thus reconfirming the result observed in an earlier
study for the first month after application [14]. Clearly,
the speed of kill of ticks of NexGard™ was not
sufficiently fast to prevent transmission of E. canis in 4
out of 32 infected tick challenges, whereas in 2 out of
32 challenges transmission was not prevented by
Bravecto™. Thus the protection results conferred
against infective tick challenges (Fig. 6) were 39.6 % for
NexGard™ and 69.8 % for Bravecto™, while Advantix®
provided 100 % protection against E. canis to dogs over
the challenge period (Table 9). Comparing results from
both the blocking and protection calculation methods
employed, results were found to be in the same order.
However, a slightly higher protection percentage was
calculated and is considered more representative as it
also considers the number of challenges with the in-
fected tick strain.
Although the published persistent speed of kill of Nex-
Gard™ [33] and Bravecto™ [34] is sufficient to prevent
transmission of the slower transmitted pathogen B.
canis, in this study for the quick transmitted E. canis we
were only able to demonstrate low partial blocking and
protection capacity. It is generally accepted that proto-
zoan parasites, such as Babesia spp., require additional
time for their sporoblasts to mature into infective sporo-
zoites in the acini of the salivary glands of the vector
ticks. Two studies have been published wherein it was
shown that both systemic compounds effectively blocked
transmission of B. canis by D. reticulatus ticks. The abil-
ity of NexGard™ to block transmission of B. canis was
determined in two groups of 8 dogs [19]. It was found
that all treated dogs remained negative for a period of
28 days, whereas all untreated control required treat-
ment for babesiosis [19]. In a similar study design, pre-
vention of transmission of B. canis by D. reticulatus
ticks to dogs orally treated with Bravecto™ was also dem-
onstrated. Eight control dogs became infected with B.
canis, but none of the eight dogs treated with Bravecto™
over a period of 12 weeks [20].
Finally, looking at the differences in transmission time
for the different tick-borne pathogens from the perspective
of risk minimization for pathogen transmission, account-
ing for the “worst case scenario” of a quickly transmitted
pathogen is considered to be a more accurate scenario for
the evaluation of a general risk prevention potential.
Conclusions
Dogs treated with the Advantix® spot-on carried signifi-
cantly less R. sanguineus ticks throughout the study as
compared with the negative controls and was with respect
to the speed of kill and resulting onset of the acaricidal ef-
ficacy superior over NexGard™ and Bravecto™ at all time
points (3 h, 6 h and 12 h) in the 12 h period observed.
Fig. 6 Diagrammatic representation of Ehrlichia canis challenge time point layout and number of animals infected per group number
Table 8 Ehrlichia canis transmission blocking efficacy
Number infected dogs (% infected) Efficacy (%)
Control Advantix® NexGard™ Bravecto™ Control versus Advantix® Control versus NexGard™ Control versus Bravecto™
6/8 (75.0) 0/8 (0) 4/8 (50.0) 2/8 (25.0) 100.0 33.3 66.7
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The speed of kill of the both systemic compounds
against R. sanguineus was not sufficiently fast to prevent
transmission of E. canis and resulted in only partial
blocking and protection capacity while Advantix® effect-
ively blocked transmission of E. canis to dogs in the
challenge period and thus provided adequate protection
for dogs against monocytic ehrlichiosis.
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